RecruitingInterventionalNot ApplicableUpdated May 22, 2026
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles | NCT00649428 | Trialant
CompletedInterventionalPhase 3Updated Mar 13, 2012
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
ClinicalTrials.gov ID
NCT00649428
Lead Sponsor
Castle Creek Biosciences, LLC.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
203Actual
Last Update Posted
Mar 13, 2012Estimated
Start Date
Oct 2006
Primary Completion Date
Jul 2008Actual
Completion Date
May 2009Actual
Brief Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.
Bilateral Nasolabial Fold Wrinkles
Autologous Human Fibroblast (azficel-T)
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is at least 18 years of age
Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol
Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol
Ability to comply with the study requirements
Negative pregnancy test (Females)
Healthy post-auricular skin for biopsy
Exclusion Criteria:
Excessive dermatochalasis of the treatment area
Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart
Total area to be treated exceeds 20 cm in length
Physical attributes which may prevent assessment or treatment as judged by the evaluator
Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study
Previous treatment with the sponsor's product
History of active autoimmune disease or organ transplantation
Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)
Active or chronic skin disease
Known genetic disorders affecting fibroblasts or collagen
Active systemic infection
Requires chronic antibiotic or steroidal therapy
Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study
Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects
Known allergic reactions to agents used in preparation of treatment
Excessive exposure to sun without adequate sun protection
Primary Purpose
Treatment
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
Triple
No central contacts
There are no central contacts for this study.
Total Skin & Beauty Dermatology Center, PC
Birmingham, Alabama, United States
Silverburg Surgical & Medical Group
Newport Beach, California 92660, United States
Dermatology Research Institute, LLC
Coral Gables, Florida, United States
River North Dermatology and Dermatologic Surgery
Naperville, Illinois, United States
Aesthetic Solutions
Chapel Hill, North Carolina, United States
Dermatology, Laser & Vein Specialists of the Carolinas